Commercial Intelligence
Commercial Performance
Combined view of sales movement, target performance and the key drivers across the business.
1 – 30 Jun 2026·All Divisions·All Regions·All Categories·Executive scope
Orbit Commercial Briefing
Updated 14 min ago
Commercial sales remain positive overall, but growth is uneven. Primary sales are +5.9% ahead of the previous period, while secondary growth has slowed to +2.8%. Gauteng North and two declining brands account for most of the target gap. Stronger sell-in than sell-out is creating stock pressure at selected wholesalers.
Net Primary Sales
R267.2m
+5.9% vs prev period
Net Secondary Sales
R281.5m
+2.8% vs prev period
Combined Target Attainment
91.7%
BelowBelow plan
Primary-to-Secondary Ratio
0.95x
Sell-in slightly below sell-out
Active Customers
4,286
+3.4% vs prev period
Revenue at Risk
R4.2m
ElevatedStock, backorders & forecast gaps
Primary & Secondary vs Target
Last 6 months · R millions
Primary
Secondary
Primary target
Secondary target
Drivers of Commercial Movement
Change vs previous period · R millions
Region × Category
Target attainment %
| Region | Cardiovascular | Respiratory | Gastrointestinal | Pain & Inflammation |
|---|---|---|---|---|
| Gauteng | 82% | 79% | 88% | 91% |
| Western Cape | 108% | 104% | 112% | 96% |
| KwaZulu-Natal | 94% | 89% | 97% | 93% |
| Eastern Cape | 86% | 88% | 90% | 82% |
| Free State | 98% | 96% | 92% | 101% |
Brand contribution
Ranked by growth this period
CardiaxolR42.8m
+24.1%
RespirezeR31.2m
+18.6%
GastravenR27.5m
+12.9%
NeurospenR19.3m
-8.4%
MetaformR22.1m
-11.2%
PulmaventR14.6m
-16.8%
Risks & opportunities
Prioritised for this period
Risks
Primary sales growing faster than secondary0.95x
Gauteng North below target-16 pp
Neurospen & Pulmavent declining 3 periods-R1.9m
Stock pressure at Wholesaler A18 days
Opportunities
Gastraven growth in Western Cape+R1.2m
KZN secondary demand strong+6.8%
Three underpenetrated key accounts+R0.9m
Range gap in independent pharmacies+R0.6m
Cross-page investigation
Follow the commercial thread
Detailed performance
Division, region, brand and product — with recommended action
| Division | Region | Brand | Product | Primary | Secondary | Target | Achv. | Growth | Cover | Risk | Action |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OTC | Gauteng | Respireze | Respireze Inhaler | R12.4m | R11.1m | R14.0m | 79% | -4.2% | 18d | warning | Reallocate stock; KAM outreach |
| Rx | Western Cape | Cardiaxol | Cardiaxol 20mg | R18.6m | R18.9m | R17.5m | 108% | +12.4% | 22d | healthy | Sustain promo; monitor cover |
| Rx | Gauteng | Cardiaxol | Cardiaxol 40mg | R9.7m | R8.4m | R10.2m | 82% | -6.1% | 9d | critical | Expedite next batch |
| Rx | KwaZulu-Natal | Gastraven | Gastraven 20mg | R7.2m | R7.6m | R6.9m | 110% | +14.2% | 31d | healthy | Extend detailing to new accounts |
| OTC | Eastern Cape | Neurospen | Neurospen 500 | R3.4m | R2.9m | R4.1m | 71% | -11.8% | 42d | warning | Review pricing and promo mix |
| Backshop | Free State | Metaform | Metaform 850 | R2.6m | R2.4m | R2.9m | 83% | -8.4% | 38d | warning | Refresh call plan |
| Rx | Gauteng | Pulmavent | Pulmavent DPI | R4.1m | R3.6m | R5.2m | 69% | -14.1% | 12d | critical | Escalate to supply planning |
| OTC | Western Cape | Gastraven | Gastraven Chewable | R5.6m | R6.1m | R5.1m | 120% | +22.3% | 24d | healthy | Expand to independents |